Everest Medicines and Hainan Herui enter commercialization collaboration for budesonide enteric capsules

PR Newswire··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Everest Medicines and Hainan Herui have entered into a commercialization collaboration for Hainan Herui's budesonide enteric capsules, which were approved by China's National Medical Products Administration in December 2025. Under the agreement, Everest Medicines will handle commercialization in the Chinese mainland market and provide technical guidance and quality audits over manufacturing and supply. The collaboration aims to enhance patient access to the combined franchise of NEFECON and Hainan Herui's budesonide enteric capsules, and is subject to customary closing conditions.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
Everest Medicines Ltd
1952
▲ PositiveDemandrelevance

Everest Medicines gains commercialization rights for budesonide enteric capsules in China, expanding its product portfolio and patient access.

Off-coverage companies 1

Hainan Herui Pharmaceutical Co., Ltd.Private▲ Positive
Demandrelevance

Hainan Herui partners with Everest to commercialize its approved budesonide capsules, leveraging Everest's sales infrastructure to reach more patients.

© 2026 MarketIVNews